Category: Press Release - Psychedelic Alpha

Numinus Wellness Inc. Reports Q4 2022 and Annual Results

Post published:December 2, 2022
Post category:Press Release

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

Post published:December 1, 2022
Post category:Press Release

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Post published:December 1, 2022
Post category:Press Release

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Post published:December 1, 2022
Post category:Press Release

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

Post published:December 1, 2022
Post category:Press Release

Small Pharma to Participate in November Investor and Healthcare Conferences

Post published:November 29, 2022
Post category:Press Release

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Post published:November 29, 2022
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Post published:November 29, 2022
Post category:Press Release

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

Post published:November 23, 2022
Post category:Press Release

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Post published:November 17, 2022
Post category:News Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Numinus Wellness Inc. Reports Q4 2022 and Annual Results

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

Small Pharma to Participate in November Investor and Healthcare Conferences

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.